Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

US pharma major Eli Lilly (NYSE: LLY) has struck a deal worth up to $870 million with Swedish biotech Camurus (Nasdaq ...

Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Eli Lilly’s engineered peptide drugs Mounjaro ... It’s partnering with Camurus, a company with technology that enables extended dosing of injectable medicines. The collaboration and license ...

Looking to defend its giant cardiometabolic health franchise, Eli Lilly is licensing a technology from Swedish biotechnology firm Camurus that promises to produce longer-acting medications.